Interestingly, in addition to an IκB kinase inhibitor (IKK-16), HDAC inhibitors (Belinostat, Romidepsin, Vorinostat) and a Proteasome inhibitor (Bortezomib), both of which were known to block NF-κB signaling were able to effectively inhibit the growth of mEPN cells, likely supporting the contribution of NF-κB activity in RELAFUS1 ependymomas [26, 33, 62]. The gene discussed is HDAC9; the disease is ependymoma.